Therapeutic Area | MeSH |
---|---|
cardiovascular diseases | D002318 |
nutritional and metabolic diseases | D009750 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
TPN | International Minerals | N-008378 DISCN | 1982-01-01 | 1 products |
Brand Name | Status | Last Update |
---|---|---|
011010 niacinamide 4% / tretinoin 0.025% | unapproved drug other | 2020-07-02 |
011013 niacinamide 4% / tretinoin 0.025% | unapproved drug other | 2020-07-02 |
011020 niacinamide 4% / tretinoin 0.05% | unapproved drug other | 2020-07-02 |
011021 niacinamide 4% / tretinoin 0.05% | unapproved drug other | 2020-07-02 |
011054 niacinamide 4% / spironolactone 5% | unapproved drug other | 2020-07-02 |
011218 niacinamide 2% / spironolactone 5% / tretinoin 0.025% | unapproved drug other | 2020-07-02 |
011220 niacinamide 2% / spironolactone 5% / tretinoin 0.05% | unapproved drug other | 2020-07-02 |
011312 niacinamide 4% / tazarotene 0.05% | unapproved drug other | 2020-07-02 |
011503 dapsone 6% / niacinamide 2% / spironolactone 5% | unapproved drug other | 2020-07-02 |
011504 dapsone 8.5% / niacinamide 4% | unapproved drug other | 2020-07-02 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Dyslipidemias | D050171 | — | — | 4 | 1 | 8 | 1 | 1 | 15 |
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 1 | 1 | — | 2 |
Coronary artery disease | D003324 | — | I25.1 | — | — | 1 | 1 | — | 2 |
Carotid artery diseases | D002340 | EFO_0003781 | — | — | 1 | — | 1 | — | 2 |
Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | 1 | — | 1 | — | 2 |
Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | — | 1 | — | 1 |
Syndrome | D013577 | — | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypercholesterolemia | D006937 | — | — | 4 | 1 | 11 | — | 1 | 17 |
Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | 2 | — | 6 | — | — | 8 |
Hyperlipoproteinemias | D006951 | — | — | — | — | 6 | — | — | 6 |
Hyperlipoproteinemia type v | D006954 | Orphanet_70470 | E78.3 | 1 | — | 3 | — | — | 4 |
Familial combined hyperlipidemia | D006950 | EFO_0000492 | E78.49 | 1 | — | 3 | — | — | 4 |
Lipidoses | D008064 | — | E75.6 | — | — | 3 | — | — | 3 |
Flushing | D005483 | — | R23.2 | — | 2 | 1 | — | — | 3 |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | 2 | — | — | 2 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | — | 1 | — | — | 2 |
Hyperlipoproteinemia type ii | D006938 | EFO_0004911 | E78.00 | 1 | — | 1 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | — | 1 |
Hodgkin disease | D006689 | — | C81 | 1 | — | — | — | — | 1 |
Drug common name | Niacinamide |
INN | nicotinamide |
Description | Nicotinamide is a pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group. It has a role as an EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor, a metabolite, a cofactor, an antioxidant, a neuroprotective agent, an EC 3.5.1.98 (histone deacetylase) inhibitor, an anti-inflammatory agent, a Sir2 inhibitor, a Saccharomyces cerevisiae metabolite, an Escherichia coli metabolite, a mouse metabolite, a human urinary metabolite and a geroprotector. It is a vitamin B3, a pyridinecarboxamide and a pyridine alkaloid. It is functionally related to a nicotinic acid. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | NC(=O)c1cccnc1 |
PDB | — |
CAS-ID | 98-92-0 |
RxCUI | — |
ChEMBL ID | CHEMBL1140 |
ChEBI ID | 17154 |
PubChem CID | 936 |
DrugBank | DB02701 |
UNII ID | 25X51I8RD4 (ChemIDplus, GSRS) |